Combination medicament of ilaprazole sodium and preparation process thereof

A technology of ilaprazole sodium and its composition, which is applied in the field of combination medicine of ilaprazole sodium and its preparation process, can solve the problems of drug oxidation hazard, incomplete pyrogen, adverse reaction of vascular stimulation, etc., and achieve drug allergy The effect of action promotion

Inactive Publication Date: 2011-05-18
吴赣英
View PDF1 Cites 14 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the freeze-dried injection of ilaprazole sodium in the prior art still adopts activated carbon depyrogenation process in the production of preparations, resulting in tiny particles of activated carbon and heavy metal ions remaining in the medicinal solution, which are brought into the blood of the human body during intravenous infusion. Bring medicinal damage to the body, and the present invention research finds, the pyrogen in the activated carbon adsorption liquid medicine is not thorough, and reason is: the one, most pharmaceutical factories adopt activated carbon to add weight to be below 0.08% of the volume of the liquid medicine; The second is that activated carbon itself does not depyrogenize and activate
This study also found that the heavy metal ions and iron ions brought by

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination medicament of ilaprazole sodium and preparation process thereof
  • Combination medicament of ilaprazole sodium and preparation process thereof
  • Combination medicament of ilaprazole sodium and preparation process thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0024] The ilaprazole sodium combined medicine provided by the invention is composed of raw material components in the following weight ratio:

[0025] Ilaprazole Sodium: 5

[0026] Weight ratio of reduced glutathione to tiopronin

[0027] 1:10 composition 20

[0028] Diammonium Glycyrrhizinate 50

[0029] Preparation Process:

[0030] 1. Dissolve ilaprazole sodium, reduced glutathione, tiopronin, and diammonium glycyrrhizinate completely with water for injection that is 100-120 times the weight of ilaprazole sodium under constant stirring;

[0031] 2. Add the activated carbon that has been removed by dry heat at 180°C to the combined drug liquid prepared in the first step, and the ratio of the weight of activated carbon to the volume of the liquid is 0.1%;

[0032] 3. The combined drug liquid is sterilized by damp heat at 121°C for 20 minutes, and when the temperature of the liquid is 60-70°C, it is filtered with a two-layer superimposed membrane with an upper layer of 0....

Embodiment 2

[0039] The ilaprazole sodium combined medicine provided by the invention is composed of raw material components in the following weight ratio:

[0040] Ilaprazole Sodium: 10

[0041] Weight ratio of reduced glutathione to tiopronin

[0042] 1:10 composition 30

[0043] Diammonium Glycyrrhizinate 60

[0044] Preparation Process:

[0045] 1. Dissolve ilaprazole sodium, reduced glutathione, tiopronin, and diammonium glycyrrhizinate completely with water for injection that is 100-120 times the weight of ilaprazole sodium under constant stirring;

[0046] 2. Add the activated carbon that has been removed by dry heat at 180°C to the combined drug liquid prepared in the first step, and the ratio of the weight of activated carbon to the volume of the liquid is 0.1%;

[0047] 3. The combined drug liquid is sterilized by damp heat at 121°C for 20 minutes, and when the temperature of the liquid is 60-70°C, it is filtered with a two-layer superimposed membrane with an upper layer of 0...

Embodiment 3

[0054] The ilaprazole sodium combined medicine provided by the invention is composed of raw material components in the following weight ratio:

[0055] Ilaprazole Sodium: 5

[0056] Weight ratio of reduced glutathione to tiopronin

[0057] 1:10 composition 30

[0058] Diammonium Glycyrrhizinate 50

[0059] Preparation Process:

[0060] 1. Dissolve ilaprazole sodium, reduced glutathione, tiopronin, and diammonium glycyrrhizinate completely with water for injection that is 100-120 times the weight of ilaprazole sodium under constant stirring;

[0061] 2. Add the activated carbon that has been removed by dry heat at 180°C to the combined drug liquid prepared in the first step, and the ratio of the weight of activated carbon to the volume of the liquid is 0.1%;

[0062] 3. The combined drug liquid is sterilized by damp heat at 121°C for 20 minutes, and when the temperature of the liquid is 60-70°C, it is filtered with a two-layer superimposed membrane with an upper layer of 0....

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention provides a combination medicament of ilaprazole sodium. The medicament is characterized by comprising the following raw materials in percentage by weight: 5-10 percent of ilaprazole sodium, 25-35 percent of reduction composition containing glutathione and tiopronin with a weight ratio of 1:10 and 45-55 percent of diammonium glycyrrhizinate. The invention also provides a preparation process of the medicament. According to a pharmaceutically acceptable dosage of the ilaprazole sodium, the combination medicament can be respectively prepared into medical preparations of the dosage forms of injections of the combination medicament of the ilaprazole sodium, freeze-drying injections of combination medicament of the ilaprazole sodium, coated tablets of the combination medicament of the ilaprazole sodium, enteric capsules, sprays, and the like and is used for treating gastric ulcer.

Description

technical field [0001] The invention relates to a combination drug of ilaprazole sodium and a preparation process thereof. Background technique [0002] The gastric and duodenal mucosa has a natural and perfect mechanism to resist the erosion of gastric acid and pepsin, but when it is damaged by Helicobacter pylori and non-steroidal anti-inflammatory drugs, peptic ulcer disease will occur. Australian scholars Warren and Marshall reveal the etiology, and have H 2 Receptor antagonist therapy drugs are effective in treatment, and 22 years later, the two were awarded the 2005 Nobel Prize in Medicine. In the 1980s, there were proton pump inhibitor drugs for the treatment of peptic ulcer disease, compared with H 2 Inhibitor treatments are more powerful and long-lasting. Ilaprazole sodium is a typical representative drug, which is currently one of the first-line first-line drugs for the treatment of peptic ulcer disease. However, the freeze-dried injection of ilaprazole sodium ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K31/4439A61K31/198A61K47/42A61K47/28A61P1/04A61K47/18
Inventor 蔡海德吴赣英
Owner 吴赣英
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap